A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue

Cancer Research

Volumn 60, Issue 3, 2000, Pages 756-759

  Mikolajczyk, Stephen D ^a   Millar, Lisa S ^a   Wang, Tang J ^a   Rittenhouse, Harry G ^a   Marks, Leonard S ^b   Song, Weitao ^c   Wheeler, Thomas M ^c   Slawin, Kevin M ^c  

^a Hybritech Incorporated   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEIN PRECURSOR;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; TISSUE DISTRIBUTION;

HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS;

EID: 0033952236     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J., Tetros, J. A., and Andriole, G. L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med., 324: 1156-1161, 1991.
2. Oesterling, J. E. Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145: 907-923, 1991.
3. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Tremblay, M., Gomez, J. L., and Emond, J. Serum prostate specific antigen as pre-screening test for prostate cancer. J. Urol., 147: 846-851, 1992.
4. Rittenhouse, H. G., Finlay, J. A., Mikolajczyk, S. D., and Partin, A. W. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit. Rev. Clin. Lab. Sci., 35: 275-368, 1998.
5. 1-antichymotrypsin. Clin. Chem., 37: 1618-1625, 1991.
6. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res., 51: 222-226, 1991.
7. Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., Lange, P. H., Subong, E. N., Parson, R. E., Gasior, G. H., Loveland, K. G., and Southwick, P. C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA, 279: 1542-1547, 1998.
8. Woodrum, D. L., Brawer, M. K., Partin, A. W., Catalona, W. J., and Southwick, P. C. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J. Urol., 159: 5-12, 1998.
9. Zhang, W. M., Leinonen, J., Kalkkinen, N., Dowell, B., and Stenman, U. H. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin. Chem., 41: 1567-1573, 1995.
10. Chen, Z., Chen, H., and Stamey, T. A. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. J. Urol., 157: 2166-2170, 1997.
11. Noldus, J., Chen, Z., and Stamey, T. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. J. Urol., 158: 1606-1609, 1997.
12. Mikolajczyk, S. D., Grauer, L. S., Millar, L. S., Hill, T. M., Kumar, A., Rittenhouse, H. G., Wolfert, R. L., and Saedi, M. S. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology, 50: 710-714, 1997.
13. McNeal, J. E. Origin and evolution of benign prostatic enlargement. Invest. Urol., 15: 340-345, 1978.
14. McNeal, J. Pathology of benign prostatic hyperplasia: insight into etiology. Urol. Clin. North Am., 17: 477-486, 1990.
15. Mikolajczyk, S. D., Millar, L. S., Wang, T. J., Wolfert, R. L., Rittenhouse, H. R., Marks, L. S., Song, W., Wheeler, T. M., and Slawin, K. M. "BPSA," a specific molecular form of free prostate specific antigen, is found predominantly in the transition zone of patients with nodular BPH. Urology, 55: 1-5, 2000.
16. Wheeler, T. M., and Lebovitz, R. M. Fresh tissue harvest for research from prostatectomy specimens. Prostate, 25: 274-279, 1994.
17. Finlay, J. A., Evans, C. L., Day, J. R., Payne, J. K., Mikolajczyk, S. D., Millar, L. S., Kuus-Reichel, K., Wolfert, R. L., and Rittenhouse, H. G. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology, 51: 804-809, 1998.
18. Grauer, L. S., Finlay, J. A., Mikolajczyk, S. D., Pusateri, K. D., and Wolfert, R. L. Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum. J. Androl., 19: 407-411, 1998.
19. Wang, T. J., Linton, H. J., Sokoloff, R. L., Grauer, L. S., Rittenhouse, H. G., and Wolfert, R. L. Antibody specificities for PSA and PSA fragments by SDS-PAGE Western blot analysis. Tumor Biol., 20: 79-85, 1999.
20. Finlay, J. A., Day, J. R., and Rittenhouse, H. G. Polyclonal, and monoclonal antibodies to prostate-specific antigen can cross-react with human kallikrein 2, and human kallikrein I. Urology, 53: 746-751, 1999.
21. Kumar, A., Mikolajczyk, S. D., Goel, A. S., Millar, L. S., and Saedi, M. S. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2 Cancer Res., 57: 3111-3114, 1997.
22. Christensson, A., Laurell, C. B., and Lilja, H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem., 194: 755-763, 1990.
23. Hilz, H., Noldus, J., Hammerer, P., Buck, F., Luck, M., and Huland, H. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors. Eur. Urol., 36: 286-292, 1999.
24. Khan, A. R., and James, M. N. G. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci., 7: 815-836, 1998.
25. Clements, J. The glandular kallikrein family of enzymes: tissue specific expression and hormonal regulation. Endocr. Rev., 10: 393-419, 1989.
26. Takayama, T. K., Fujikawa, K., and Davie, E. W. Characterization of the precursor of prostate-specific antigen-activation by trypsin and by human glandular kallikrein. J. Biol. Chem., 272: 21582-21588, 1997.
27. Lovgren, J., Rajakoski, K., Karp, M., Lundwall, A., and Lilja, H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem. Biophys. Res. Commun., 238: 549-555, 1997.
28. Mikolajczyk, S. D., Millar, L. S., Marker, K. M., Rittenhouse, H. G., Wolfert, R. L., Marks, L. S., Charlesworth, M. C., and Tindall, D. J. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue. Cancer Res., 59: 3927-3930, 1999.